Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05276063 · ClinicalTrials.gov registry record · Phase 2
A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
A Phase 2 study of Eye Diseases and Thyroid Eye Disease, sponsored by Sling Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 20
- Study locations
NCT05276063: Active Phase 2 study of Eye Diseases and Thyroid Eye Disease, sponsored by Sling Therapeutics.
NCT05276063 is a Phase 2 study of Eye Diseases and Thyroid Eye Disease that is active but no longer recruiting, run by Sling Therapeutics. The registered enrollment target is 90 participants, below the 741,299-participant average among 27 other Eye Diseases trials with a reported enrollment target (100% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05276063, a Phase 2 study of Eye Diseases and Thyroid Eye Disease, is active but no longer recruiting, sponsored by Sling Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 20
- Study locations
Study Summary
The overall objective is to study the safety, pharmacokinetics and efficacy of linsitinib (a small molecule IGF-1R inhibitor) administered orally twice daily (BID) vs. placebo, at 24 weeks in the treatment of subjects with active, moderate to severe thyroid eye disease (TED).
Primary Outcome
Proptosis response is defined as a ≥ 2 mm reduction from Baseline in the primary study eye without deterioration (≥ 2 mm increase) of proptosis in the contralateral non-study eye.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Linsitinib
Study Locations (20)
California
- Thrive Health Research - Beverly Hills
- UC San Diego Health - La Jolla
- UCLA - Los Angeles
- Byers Eye Institute - Stanford University - Palo Alto
Florida
- Bascom Palmer Eye Institute - Miami
- Center for Excellence in Eye Care - Miami
- Sarasota Retina Institute - Sarasota
Michigan
- Kellogg Eye Center - Ann Arbor
- Kahana Oculoplastic & Orbital Surgery - Livonia
Illinois
- Chicago Oculofacial Plastic Surgery - Chicago
Iowa
- Wolfe Eye Clinic - West Des Moines
Massachusetts
- Mass Eye and Ear - Boston
Missouri
- Washington University in St. Louis/Barnes Jewish Hospital - Creve Coeur
New York
- Columbia University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2022-07-01 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
What the registry record for NCT05276063 still lists
NCT05276063 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 741,299-participant average among 27 other Eye Diseases trials with a reported enrollment target (100% lower).
The record links to 10 conditions, with Eye Diseases appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05276063 names 20 study sites across 14 states, led by California, Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT05276063 about?
NCT05276063 is a clinical study titled "A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)". The overall objective is to study the safety, pharmacokinetics and efficacy of linsitinib (a small molecule IGF-1R inhibitor) administered orally twice daily (BID) vs. placebo, at 24 weeks in the treatment of subjects with active, moderate to severe thyroid eye disease (TED).
What is the current status of trial NCT05276063?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2022-07-01. Estimated completion is 2026-09.
What conditions does trial NCT05276063 study?
This clinical trial studies the following conditions: Eye Diseases, Thyroid Eye Disease, Endocrine System Diseases, Graves Ophthalmopathy, Thyroid Diseases.
What interventions are being tested in trial NCT05276063?
The interventions under investigation include: Placebo (DRUG), Linsitinib (DRUG).
Who is sponsoring clinical trial NCT05276063?
This trial is sponsored by Sling Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05276063 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Iowa, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eye Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05276063's enrollment target sits among peer trials
90 12th of 27 higher than 16 of 27 other Eye Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Eye Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SGLT2 Inhibitors in Geographic Atrophy
RECRUITING · Phase 2
-
Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
RECRUITING · Phase 2
-
A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)
ACTIVE NOT RECRUITING · Phase 2
-
Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]
COMPLETED · Phase 2
-
Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia
COMPLETED · Phase 2
-
Anecortave Acetate for Treatment of Steroid Induced Intraocular Pressure (IOP) Elevation
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI